INK 128 (MLN0128)

Catalog No.S2811

INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

Price Stock Quantity  
USD 221 In stock
USD 170 In stock
USD 270 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

INK 128 (MLN0128) Chemical Structure

INK 128 (MLN0128) Chemical Structure
Molecular Weight: 309.33

Validation & Quality Control

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

INK 128 (MLN0128) is available in the following compound libraries:

mTOR Inhibitors with Unique Features

Product Information

  • Compare mTOR Inhibitors
    Compare mTOR Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.
Targets mTOR [3]
(Cell-free assay)
mTOR [3]
(Cell-free assay)
PI3Kα [3]
(Cell-free assay)
PI3Kγ [3]
(Cell-free assay)

 View  More

IC50 1.4 nM(Ki) 1.4 nM(Ki) 219 nM 221 nM
In vitro INK 128 exhibits an enzymatic inhibition activity against mTOR and more than 100-fold selectivity to PI3K kinases. [1] As TORC1/2 inhibitor, INK 128 inhibits both the phosphorylation of S6 and 4EBP1, the downstream substrates of TORC1, and selectively inhibits AKT phosphorylation at Ser473, the downstream substrate of TORC2. Furthermore, INK 128 also shows potent inhibition effects on cell lines resistant to rapamycin and pan-PI3K inhibitors. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
PANC-1 MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>MYWxMVExOCCwTR?=MkfsO|IhcA>?MWHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6MXuyOFk4OTV2NB?=
PANC-1 Mo\UR4VtdCCYaXHibYxqfHliQYPzZZk>NGG2V5I2OCCwTR?=NGLpepEzPC17NjDoM{jz[IlvcGmkaYTzJINmdGxidnnhZoltcXS7IITpcYUh\GWyZX7k[Y51dHl?M1HCclI1QTdzNUS0
MIA PaCa-2NHvZZ3NE\WyuIG\pZYJqdGm2eTDBd5NigQ>?NVT4cJYzOS1zMECgcm0>M3HJZVczKGh?NX25S5Z2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=NUj6U401OjR7N{G1OFQ>
PANC-1 M4PYe2Fxd3C2b4Ppd{BCe3OjeR?=NHzqTGYyOC1zMECgcm0>NXSyOJpqPzJiaB?=MYfpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7NFPUcnYzPDl5MUW0OC=>
PANC-1 Ml3NSpVv[3Srb36gRZN{[Xl?NXvnN5dKOTBxNUCgcm0>MojSNlQhcA>?NIfxOoNlemGvYYTpZ4FtdHliaX7obYJqfHNicHjvd5Bpd3K7bHH0bY9vKG:oIETFMWJROS2VNluxJEhuXE:UQ{GgZYN1cX[jdHnvckBqdmSrY3H0c5J{MSCjbnSgRYt1KGG2IGPldkA1PzNiKITo[UBuXE:UQ{KgZYN1cX[jdHnvckBqdmSrY3H0c5IqNW\D[o5FOjR7N{G1OFQ>
PANC-1 M1:zbmZ2dmO2aX;uJGF{e2G7MX:1NEBvVQ>?NH\lUHU1QCCqM{XHXoRqe3K3cITzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25?M4fPbFI1QTdzNUS0
PANC-1 NYXjVmNlTnWwY4Tpc44hSXO|YYm=MWqxNEBvVQ>?MUi3NkBpNGPGfFZqdmO{ZXHz[ZMh\2WvY3n0ZYJqdmVic3Xud4l1cX[rdIm=MXGyOFk4OTV2NB?=

... Click to View More Cell Line Experimental Data

In vivo In a ZR-75-1 breast cancer xenograft model, INK 128 shows tumor growth inhibition efficacy at a dose of 0.3 mg/kg/day. [1] Daily, oral administration of INK 128 inhibits angiogenesis and tumor growth in multiplexenograft models. [2]
Features

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Liu A, et al. Drug Discovery Today: Therapeutic Strategies. 2009, 6(2), 47-55.

[2] Jessen K, et al. Mol Cancer Ther. 2009, 8(12), Meeting Abstract Supplement.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-05-07)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02756364 Not yet recruiting Breast Neoplasms Millennium Pharmaceuticals, Inc. June 2016 Phase 2
NCT02725268 Not yet recruiting Endometrial Neoplasms Millennium Pharmaceuticals, Inc.|European Network of Tran  ...more Millennium Pharmaceuticals, Inc.|European Network of Translational Research in Ovarian Cancer - EUTROC|European Network of Individualized Treatment in Endometrial Cancer - ENITEC June 2016 Phase 2
NCT02724020 Not yet recruiting Clear-cell Metastatic Renal Cell Carcinoma Millennium Pharmaceuticals, Inc. June 2016 Phase 2
NCT02719691 Not yet recruiting Metastatic Breast Cancer|Solid Tumors University of Colorado, Denver April 2016 Phase 1
NCT02619669 Not yet recruiting Breast Cancer Dartmouth-Hitchcock Medical Center December 2015 Phase 1

view more

Chemical Information

Download INK 128 (MLN0128) SDF
Molecular Weight (MW) 309.33
Formula

C15H15N7O

CAS No. 1224844-38-5
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 62 mg/mL (200.43 mM)
Ethanol 2 mg/mL (6.46 mM)
Water <1 mg/mL (<1 mM)
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 3-(2-aminobenzo[d]oxazol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

Customer Product Validation (3)


Click to enlarge
Rating
Source Biochem Biophys Res Commun 2013 440(4), 701-6. INK 128 (MLN0128) purchased from Selleck
Method CCK-8 cell viability assay
Cell Lines Hep-2, SCC-9 cells
Concentrations 0.1 uM
Incubation Time 72 h
Results It found that AZD8055 was more potent than mTORC1 inhibitor rapamycin and Akt/mTOR dual inhibitor LY 294002 in killing of Hep-2 (D) and SCC-9 (E) cells. AZD2014 and INK-128, two other mTORC1/mTORC2 dual inhibitors, were also shown to inhibit the survival of Hep-2 and SCC-9 cells (D and E).

Click to enlarge
Rating
Source Antonino Maria Spart from University of Bologn. INK 128 (MLN0128) purchased from Selleck
Method Western Blot/MTT
Cell Lines Molt-4 leukemia cell
Concentrations 1.9 μM
Incubation Time 48 h
Results PI3K Inhibitor INK-128 was able to block Molt-4 leukemia cell line proliferation after 48 h with a measured IC50 of around 1.9 mM. Apoptosis induction assessed by western blot, demonstrated a limited cleavage of Caspase 7.

Click to enlarge
Rating
Source INK 128 (MLN0128) purchased from Selleck
Method ELISA
Cell Lines Bone marrow derived macrophages
Concentrations 1 nM
Incubation Time 1 h
Results

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related mTOR Products

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • KU-0063794

    KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Recently Viewed Items

Tags: buy INK 128 (MLN0128) | INK 128 (MLN0128) supplier | purchase INK 128 (MLN0128) | INK 128 (MLN0128) cost | INK 128 (MLN0128) manufacturer | order INK 128 (MLN0128) | INK 128 (MLN0128) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us